Study Help for the CIP Exam As the application deadline for the Fall 2020 CIP examination approaches (14 August for the exam window of 7…
Study Help for the CIP Exam As the application deadline for the Fall 2020 CIP examination approaches (14 August for the exam window of 7…
The HHS has released HHS Initiatives to Address the Disparate Impact of COVID-19 on African Americans and Other Racial and Ethnic Minorities. It covers the…
In order to support response efforts to this pandemic, the FDA has issued guidance to provide non-binding recommendations regarding the key factors and procedures IRBs…
Read AI, Robots, and Ethics in the Age of COVID-19 published by MIT’s “Sloan Management Review” for an expert’s perspective on the impact of robots…
Kelly Willenberg, DBA, RN, CCRP, CHRC, CHC is one of CITI Program’s expert contributors in clinical trial billing. As a respected expert in the research…
According to the authors of a recently published article in the New England Journal of Medicine, findings from the Adaptive COVID-19 Treatment Trial, support remdesivir…
At 12 PM ET on Thursday, June 18, CTTI will host Engaging Racial and Ethnic Minority Patient Populations in COVID-19 Clinical Trials. The webinar will…
In an NIH clinical trial involving 1063 patients with advanced COVID-19, preliminary results indicate that those who received broad-spectrum antiviral treatment Remdesivir recovered 31% faster…
In recent weeks biotech and clinical research communities have pivoted resources toward developing vaccines against SARS-CoV-2. Teams around the world are researching various methods of…
Charles Hennekens, MD, DrPH is one of the expert authors of CITI Program’s Essentials of Public Health Research course. As a respected expert on public…
FDA Guidance on Conduct of Clinical Trials of Medical Products during COVID-19 Public Health Emergency was released in March for industry, investigators, and institutional review…
This clinical trial will test the safety and efficacy of a treatment regimen of the remdesivir plus the anti-inflammatory drug baricitinib for COVID-19. It is…